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Abstract
Background: The primary objective was to investigate prevalence of subclinical atherosclerosis in Korean
individuals with diabetes and hyperlipidemia. Association of subclinical atherosclerosis with cardiovascular risk
was assessed.
Methods: Assessments of carotid artery intima media thickness (cIMT) and atheromatous plaque were done using
B-mode ultrasonography. Subclinical atherosclerosis was diagnosed based on presence of plaque, and/or increased
cIMT versus mean cIMT reference values for Korean healthy controls. Atherosclerosis risk factors were analyzed
using United Kingdom Prospective Diabetes Study (UKPDS) risk engine and Framingham Risk Score.
Results: In total, 355 patients were included; increased mean cIMT was observed in 15.3 % of patients, 69 % had >1
carotid artery plaque, and 72.7 % were diagnosed with subclinical atherosclerosis. In total, 60 % of subjects were taking
statins, with low-density lipoprotein cholesterol level maintained ~80 mg/dL at enrollment. Carotid artery measures
were well correlated with UKPDS and Framingham risk scores. Prevalence of subclinical atherosclerosis in the low risk
group (<15 % 10-year UKPDS-predicted coronary heart disease risk) was 64.7 %; higher than predicted in previous
studies. In multivariate analysis, advanced age was a significant risk factor for subclinical atherosclerosis in men and
women, while increased waist circumference and longer diabetes duration were independent predictors only
in women.
Conclusion: Subclinical atherosclerosis is more prevalent among individuals with both diabetes and hyperlipidemia
than in diabetic patients without additional cardiovascular risk factors. As conventional risk engines, based on
modifiable risk factors may underestimate cardiovascular risk, early non-invasive carotid artery imaging screening may
be warranted for patients with diabetes and hyperlipidemia, especially if they are elderly, have central obesity or have
long duration of diabetes.
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Background
Patients with diabetes show increased morbidity and
mortality from atherosclerotic diseases [1]. Coronary ar-
tery disease in diabetic patients is associated with trad-
itional risk factors, including dyslipidemia, hypertension,
poor glycemic control, obesity, and smoking [2]. Fur-
thermore, atherosclerotic complications in diabetes are
mediated by abnormalities in endothelial and vascular
smooth muscle cell function caused by metabolic abnor-
malities such as hyperglycemia, increase of free fatty
acids, and insulin resistance [3–5].
Sudden death is a common manifestation of coronary
heart disease (CHD) [6]. Therefore, there is a great inter-
est in identifying asymptomatic individuals at risk who
would be candidates for more intensive and evidence-
based medical interventions [7]. B-mode ultrasound
measurement of carotid intima media thickness (cIMT)
is a non-invasive method for estimating atherosclerotic
burden, with increased cIMT or the presence of ather-
omatous plaque predicting CHD and stroke after adjust-
ment for other risk factors [8, 9]. In a study of a
multiethnic population, 23 % of individuals classified as
being at low risk for CHD by Framingham Risk Score
had subclinical atherosclerosis, emphasizing the need for
non-invasive assessment of atherosclerotic burden in
risk prediction [10].
Consistent with the increased incidence of cardiovas-
cular disease (CVD) in diabetic patients, cIMT is in-
creased in patients with diabetes compared with those
without diabetes. In a study of 826 subjects aged 40–79
years, impaired glucose tolerance and diabetes were in-
dependent predictors of advanced stenotic carotid ath-
erosclerosis [11]. Also, cIMT was significantly greater in
elderly patients (aged 67 years on average) with diabetes
than in control subjects [12]. In the Atherosclerosis Risk
in Communities (ARIC) study, patients with diabetes
had significantly increased cIMT compared with those
without diabetes regardless of prior myocardial infarc-
tion (MI), and non-diabetic patients with MI had cIMT
similar to that of diabetic patients without MI [13]. In a
study of Koreans, 43.5 % of patients with diabetes had
increased cIMT, and it was associated with elevated risk
of CHD, stroke, and peripheral artery disease [14]. How-
ever, there was no further evaluation of risk stratification
or plaque status.
Therefore, in contrast to previous studies, we recruited
Korean patients who simultaneously had two major car-
diovascular (CV) risk factors, diabetes and hyperlipid-
emia, but did not have symptomatic CVD or any other
major vascular disease. We evaluated the prevalence of
subclinical atherosclerosis in this specific patient group
with high CV risk. Subclinical atherosclerosis was de-
fined by the increase of cIMT or the presence of ather-
omatous plaque, according to the result of carotid artery
ultrasonography. We also investigated the associated risk
factors for subclinical atherosclerosis and analyzed risk
stratification by conventional CV risk predictors.
Methods
The Prevalence of Subclinical Atherosclerosis and its
Associated Factors in Hyperlipidemic Korean Adults
with Diabetes (ALTO) study (NCT01264263) is a multi-
center, cross-sectional investigation of subclinical ath-
erosclerosis by cIMT and its associated factors in six
university-affiliated hospitals in Korea.
Study population
All study participants were randomly enrolled from six
university-affiliated hospitals on an endocrinologic basis.
The following ethics committees/institutional review
boards (IRBs) of the participating institutions approved
the study protocol: Hallym University Dongtan Sacred
Heart Hospital Ethics Committee/IRB, Hwaseong-si,
Gyeonggi-do, Korea; Hallym University Sacred Heart
Hospital Ethics Committee/IRB, Anyang-si, Gyeonggi-do,
Korea; The Catholic University of Korea, Yeouido St.
Mary’s Hospital Ethics Committee/IRB, Seoul, Korea;
Korea University Anam Hospital Ethics Committee/IRB,
Seoul, Korea; Inje University Ilsan Paik Hospital Ethics
Committee/IRB, Goyang-si, Gyeonggi-do, Korea; Hanyang
University Hospital Ethics Committee/IRB, Seoul, Korea.
All participants provided written informed consent.
Patients aged 20–80 years who had diabetes and
hyperlipidemia were enrolled. We excluded all partici-
pants with a prior history of any CVD defined as MI,
silent MI, angina, prior percutaneous coronary interven-
tion or coronary artery bypass graft surgery, or history
of stroke or peripheral artery disease. Participants who
had malignancy, chronic inflammatory disease, impaired
renal or liver function, or history of taking non-steroidal
anti-inflammatory drugs that could affect high-
sensitivity C-reactive protein (hsCRP) level, and patients
who used steroids for 7 consecutive days within the pre-
vious 90 days were also excluded. Diabetes was defined
as the use of any anti-diabetic drugs, including oral
hypoglycemic agents and insulin, or fasting plasma glu-
cose concentration ≥126 mg/dL, or plasma glucose
≥200 mg/dl on a 2-hour oral glucose tolerance test.
Hyperlipidemia was defined as total cholesterol
≥200 mg/dL, triglycerides ≥150 mg/dL, or low-density
lipoprotein cholesterol (LDL-C) ≥100 mg/dL according
to the National Cholesterol Education Program (NCEP)
Adult Treatment Panel III guidelines, or if the patient
was taking anti-hyperlipidemic medications.
Assessment of risk factors
Demographics, lifestyle, and medical history were ob-
tained using a self-reported questionnaire. Body weight
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and height were measured with subjects wearing light-
weight clothes. Body mass index (BMI) was calculated as
weight (kg) divided by height (m). Waist circumference
was measured by a plastic tape measure placed in the
middle between the lowest margin of the ribs and the
upper margin of the iliac crest with subjects standing
with their feet 30 cm apart. Blood pressure was mea-
sured twice on the left arm after the subjects rested for
at least 10 min in a sitting position, and the mean value
of the two measurements was used. Smoking status was
evaluated by the US Centers for Disease Control and
Prevention, based on questionnaire responses regarding
smoking habit. Subjects who had smoked at least 100
cigarettes in their lifetime and who, at the time of sur-
vey, smoked either every day or some days were defined
as a “current smoker”. Subjects who reported smoking
at least 100 cigarettes in their lifetime but who did not
smoke at all at the time of the survey were defined as a
“former smoker”. Patients who had never smoked a
cigarette or who smoked fewer than 100 cigarettes were
defined as “never a smoker”.
All of the blood samples were taken after 12–16 hours
of fasting and analyzed within 24 hours of transportation
to the central laboratory (Green Cross Reference
Laboratory, Seoul, Korea). Fasting plasma glucose level
was measured by hexokinase method (Modular Analytics,
Roche Diagnostics, Mannheim, Germany). High-
performance liquid chromatography (Variant II TURBO,
Bio Rad, Hercules, California, USA) was used for the
measurement of glycated hemoglobin (HbA1c) level and
total cholesterol, triglyceride, high-density lipoprotein
cholesterol (HDL-C) and LDL-C were measured by en-
zymatic colorimetric assay (Modular Analytics, Roche
Diagnostics, Mannheim, Germany). Apolipoprotein A1,
apolipoprotein B, hsCRP, urinary albumin and creatinine
for the diagnosis of albuminuria were measured by
immunoturbidimetric assay (Modular Analytics, Roche
Diagnostics, Mannheim, Germany).
Carotid ultrasonography
Carotid artery atherosclerosis was determined by one
examiner for all patients across all six sites, using high-
resolution B-mode ultrasound (M-Turbo®, SonoSite,
Washington, Bothell, USA), according to protocol [15].
A transverse scan was followed by a longitudinal circum-
ferential scan at 12 well-defined segments, the near and
the far walls of the right and left common carotid, bulb,
and internal carotid arteries. Circumferential plaque was
screened from three imaging angles: anterior, lateral, and
posterior. cIMT was measured at the far walls of the dis-
tal 1 cm of each common carotid artery at three imaging
angles, and the mean and maximum cIMT values were
measured by leading edge-to-edge method. Plaque was
defined as a focal structure encroaching into the arterial
lumen of at least 0.5 mm or 50 % of the surrounding
cIMT value or a demonstrating thickness >1.5 mm as
measured from the media-adventitia interface to the
intima-lumen interface [16].
The mean maximum value of cIMT in each study sub-
ject (described as mean cIMT) was calculated based on
the average of maximum cIMT values within the 12 ar-
terial wall segments. The mean value was then compared
with the mean value (average value of maximal cIMT) in
757 healthy Korean subjects, with corresponding age
and sex as the reference [17]; these cut-off values were
used to define subclinical atherosclerosis in the current
study (Additional file 1: Table S1).
United Kingdom prospective diabetes study and
Framingham Risk Score calculation
The United Kingdom Prospective Diabetes Study
(UKPDS) risk engine (ver. 2.0) was downloaded from the
website (http://ukpds-risk-engine.software.informer.com/
2.0/) and used to analyze the data. The Framingham Risk
Score was calculated using the equation for estimating
10-year CVD risk [18].
Statistical analysis
Statistical analyses were performed using SPSS V16.0.
For continuous variables, an analysis of covariance was
used, and the chi-squared test was used in the categor-
ical data analysis. Continuous variables which did not
show normal distribution were log-transformed before
statistical tests were performed. All statistical tests were
two-sided. Pearson correlation analysis was used to de-
termine the relationships between CV risk scores and
cIMT measures. The association between conventional
risk scores and subclinical atherosclerosis was evaluated
through calculating the area under the receiver operating
characteristic (ROC) curve at different levels of risk
scores. The statistical significance of the difference in
area under the curve (AUC) was calculated by the
MedCalc software (http://www.medcalc.org/). Predictors
of subclinical atherosclerosis were obtained by logistic re-
gression analysis, following consideration of additive or
confounding factors. Values in the text are the mean ±
standard deviation, unless otherwise specified.
Results
Characteristics of study subjects
A total of 362 diabetic patients aged 20–80 years with
hyperlipidemia were initially enrolled. The data of 355
participants without established or previous CVD were
eligible for analysis after exclusion of seven patients who
did not match the protocol guidelines. Clinical and la-
boratory characteristics of study subjects were analyzed
by sex (Table 1). Women (n = 178, 60.2 ± 10.2 years)
were significantly older than men (n = 177, 55.9 ±
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10.9 years) but the mean durations of diabetes were not
significantly different (women 8.1 ± 7.3 vs men 7.5 ±
7.3 years, p = 0.143). Also, mean BMI was similar, but
waist circumference was significantly bigger in men
(90.6 ± 7.0 vs women 86.3 ± 10.0 cm). Fasting plasma
glucose level and HbA1c of total study subjects were
136.2 ± 40.7 mg/dL and 7.4 ± 1.1 %, respectively, with no
significant differences between men and women. In the
lipid analysis, both total cholesterol and HDL-C were
significantly higher in women than in men (169.8 ± 34.3
vs 160.9 ± 32.9 mg/dL, 54.8 ± 12.8 vs 49.3 ± 11.2 mg/dL,
respectively). hsCRP was 0.5 ± 0.9 mg/L and mean ran-
dom urine albumin to creatinine ratio was not signifi-
cant. Among men, 140 (78.7 %) of 177 were current or
previous smokers, but among women only eight (4.5 %)
of 178 were current or previous smokers. Statins were
prescribed in 237 (66.8 %) of 355 study subjects.
Prevalence of subclinical atherosclerosis in patients with
type 2 diabetes and dyslipidemia
The mean and maximum cIMT and the number of pla-
ques in study subjects are shown in Table 2 and the
mean cIMT according to age and sex is shown in Fig. 1.
The mean cIMT was 0.61 ± 0.11 mm in men and 0.59 ±
0.12 mm in women (p =NS). A total of 54 (15.3 %) of
354 study subjects had increased cIMT when compared
with the healthy control reference values [17]. The mean
number of plaques was 1.89 ± 2.46 in men and 1.42 ±
1.59 in women (p = 0.034) (Table 2). Sixty-nine percent
of all patients were found to have one or more plaques
(70.8 % in men and 67.2 % in women) (Table 2).
Based on comparison versus healthy Korean subjects
with corresponding age and sex [17], the prevalence of
subclinical atherosclerosis was 72.7 % in total partici-
pants (74.7 % in men vs 70.6 % in women, respectively)
(Table 3).
Correlation analysis between cIMT measures and
conventional CV risk engine score
The correlations between the two most popular CV risk
assessment engines, UKPDS and Framingham risk scor-
ing systems, and cIMT measures, were evaluated. Mean
and maximum cIMT and the number of carotid plaques
were significantly correlated with both UKPDS and
Framingham Risk Scores (Additional file 1: Table S2).
ROC curve analysis showed a slight trend towards better
correlation between UKPDS and cIMT measures from
AUC calculation, compared with Framingham risk pre-
diction, although it was not statistically significant (AUC
0.667 vs 0.636, respectively; p = 0.189, Additional file 1:
Figure S1).
We separated subjects into low- and high-risk groups
by the cut-off point of 15 % 10-year CHD risk according
to the UKPDS risk engine, and compared cIMT and
plaque status in each study group. As shown in
Additional file 1: Table S3, mean cIMT and the presence
and the number of plaques were all significantly higher
in the high-risk group.
The prevalence of subclinical atherosclerosis by UKPDS
10-year CHD risk stratification
Table 4 shows the prevalence of subclinical atheroscler-
osis according to UKPDS risk group by sex. Approxi-
mately 81.5 % of participants estimated to be at high risk
by the UKPDS risk engine had subclinical atheroscler-
osis. However, 64.7 % of the low risk patients also had
subclinical atherosclerosis.
Predictors of subclinical atherosclerosis in patients with
type 2 diabetes and hyperlipidemia
We stratified study subjects by sex and explored clinical
predictors of subclinical atherosclerosis in univariate and
Table 1 Baseline clinical and laboratory characteristics of
study participants
Men Women p-value
(n = 178) (n = 177)
Age (years) 55.9 ± 10.9 60.2 ± 10.2 <0.001
Body mass index (kg/m2) 25.5 ± 3.1 25.2 ± 4.0 0.468
Waist circumference (cm) 90.6 ± 7.0 86.3 ± 10.0 <0.001
Duration of diabetes (years) 7.5 ± 7.3 8.6 ± 7.3 0.143
Systolic blood pressure (mmHg) 128.7 ± 13.5 128.2 ± 14.2 0.726
Diastolic blood pressure (mmHg) 79.3 ± 9.6 78.2 ± 8.9 0.257
Smoking, (never/ex/current) 38/72/68 169/2/6 <0.001
Family history of CHD (%) 12 (6.7) 9 (5.1) 0.654
Menopause – 139 (78.5) –
Atrial fibrillation (%) 2 (1.1) 2 (1.1) 0.686
ACE inhibition (%) 61 (34.3) 70 (39.5) 0.323
Antiplatelet medication (%) 51 (28.7) 44 (24.9) 0.472
Statin use (%) 114 (64) 123 (69.5) 0.311
Total cholesterol (mg/dL) 160.9 ± 32.9 169.8 ± 34.3 0.013
Triglycerides (md/dL) 155.3 ± 116.9 138.1 ± 81.3 0.108
HDL-C (mg/dL) 49.3 ± 11.2 54.8 ± 12.8 <0.001
LDL-C (mg/dL) 85.7 ± 28.7 91.3 ± 28.0 0.061
ApoB (mg/dL) 71.3 ± 21.4 71.8 ± 20.3 0.813
ApoA1 (mg/dL) 130.0 ± 27.4 137.8 ± 2.8 0.006
Fasting blood glucose (mg/dL) 137.0 ± 41.9 135.3 ± 39.6 0.694
HbA1c (%) 7.4 ± 1.1 7.5 ± 1.2 0.449
hsCRP (mg/L)a 0.5 ± 0.9 0.5 ± 0.9 0.618
Albumin/creatinine ratioa 12.1 ± 26.7 12.1 ± 28.6 0.239b
Values are mean ± SD; aMedian ± IQR; bThe variable was log transformed
before statistical analysis
ACE, angiostensin-converting enzyme; Apo, apolipoprotein; CHD, coronary
heart disease; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein
cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range;
LDL-C, low density lipoprotein cholesterol; SD, standard deviation
Hong et al. BMC Cardiovascular Disorders  (2015) 15:114 Page 4 of 8
multivariate logistic regression models (Additional file 1:
Tables S4 and S5). In men, only advanced age was a sig-
nificant predictor of subclinical atherosclerosis (odds ra-
tio [OR] 1.05, 95 % confidence interval [CI] 1.017–1.084,
p < 0.005), while advanced age (OR 1.061, 95 % CI
1.025–1.098, p = 0.001), longer duration of diabetes (OR
1.098, 95 % CI 1.02–1.181, p = 0.013) and increased waist
circumference (OR 1.051, 95 % CI 1.008–1.096, p = 0.02)
were independent predictors of subclinical atheroscler-
osis in women.
Discussion
A total of 355 diabetic patients with hyperlipidemia were
recruited in our study and underwent B-mode ultra-
sound measurement of cIMT. The main finding was the
high prevalence of subclinical atherosclerosis in Korean
patients with diabetes and hyperlipidemia; 72.7 % of
study patients had asymptomatic atherosclerosis with an
increase in cIMT and/or carotid artery plaques assessed
by non-invasive imaging.
Patients with diabetes and hyperlipidemia are classified
as high-risk groups by the NCEP guideline, and the
committee recommends lower LDL-C level treatment
goals regardless of atheroma burden [19]. Evaluation of
atherosclerotic burden by non-invasive imaging has not
been incorporated in clinical practice. Also, current
guidelines for primary prevention of CVD recommend
the use of traditional CV risk factors in initial risk strati-
fication [19–21]. However, the most commonly used
Framingham Risk Score is reported to underestimate CV
Table 2 cIMT and plaque measures in patients with diabetes and hyperlipidemia
Total Men Women p-value
Age (years) n n
Mean cIMT (mm)
<40 0.522 ± 0.086 12 0.525 ± 0.069 7 0.514 ± 0.114
40–49 0.532 ± 0.090 39 0.555 ± 0.089 21 0.489 ± 0.076
50–59 0.586 ± 0.101 60 0.589 ± 0.084 54 0.582 ± 0.118
60–69 0.612 ± 0.114 44 0.650 ± 0.124 61 0.585 ± 0.098
≥70 0.691 ± 0.116 23 0.737 ± 0.066 33 0.677 ± 0.122†
Total 0.598 ± 0.116 178 0.610 ± 0.110 177 0.587 ± 0.119 0.082
Max cIMT (mm)
<40 0.526 ± 0.087 12 0.532 ± 0.072 7 0.514 ± 0.114
40–49 0.532 ± 0.090 39 0.555 ± 0.090 21 0.489 ± 0.076
50–59 0.600 ± 0.132 60 0.603 ± 0.120 54 0.597 ± 0.145
60–69 0.617 ± 0.125 44 0.661 ± 0.145 61 0.585 ± 0.098
≥70 0.705 ± 0.141 23 0.736 ± 0.157 34 0.684 ± 0.126a
Total 0.606 ± 0.134 178 0.619 ± 0.137 177 0.593 ± 0.130 0.062
Plaque (presence, %)
<40 8/19 (42.1) 12 6/12 (50.0) 7 2/7 (28.6)
40–49 30/60 (50.0) 39 20/39 (51.3) 21 10/21 (47.6)
50–59 74/114 (64.9) 60 41/60 (68.3) 54 33/54 (61.1)
60–69 84/105 (80.0) 44 39/44 (88.6) 61 45/61 (73.8)
≥70 49/57 (86.0) 23 20/23 (87.0) 34 29/34 (85.3)
Total 245/355 (69.0) 178 126/178 (70.8) 177 119/177 (67.2) 0.469
Plaque (number)
<40 0.526 ± 0.697 12 0.583 ± 0.669 7 0.429 ± 0.787
40–49 0.700 ± 0.830 39 0.718 ± 0.826 21 0.667 ± 0.856
50–59 1.377 ± 1.502 60 1.600 ± 1.639 54 1.130 ± 1.304
60–69 2.257 ± 2.756 44 3.273 ± 3.681 61 1.525 ± 1.468
≥70 2.509 ± 2.213 23 2.696 ± 2.363 34 2.382 ± 2.132
Total 1.659 ± 2.083 178 1.893 ± 2.462 177 1.424 ± 1.587 0.034
aOne study subject who had mean and maximum cIMT of 2 mm was excluded as an outlier
cIMT, carotid intima media thickness
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risk in patients with diabetes [22] and the UKPDS risk
engine may not provide reliable risk estimate among pa-
tients with diabetes in the era of widespread use of sta-
tins that modify cholesterol levels [23]. Of note, several
large-scale studies have addressed the relationship be-
tween cIMT and CV events. In the ARIC study, cIMT
≥1 mm was associated with an increase in CHD by five-
fold in women and two-fold in men after adjusting for
age, social group, and race [24]. The Cardiovascular
Health Study reported the elevated risk of MI or stroke
with increase in cIMT among study participants
>65 years of age [25]. In the Rotterdam Study, carotid
plaques, cIMT, aortic atherosclerosis, and lower-
extremity atherosclerosis were equally predictive of fu-
ture MI [26, 27]. Consequently, a recent guideline
(Screening for Heart Attack Prevention and Education)
recommends the non-invasive screening of all asymp-
tomatic men 45–75 years of age and asymptomatic
women 55–75 years of age at initial risk stratification
[28].
In our study, 60 % of study subjects were taking statins
and LDL-C was already maintained around 80 mg/dL at
enrollment. In the low-risk group, estimated to have
<15 % 10-year CHD risk by the UKPDS risk engine, a
higher proportion of patients (64.7 %) had subclinical
atherosclerosis. This suggests that the conventional risk-
prediction algorithm based on modifiable risk factors
may underestimate CV risk in patients with diabetes and
hyperlipidemia, especially when LDL-C is maintained at
the currently recommended target. This may also
emphasize the value of non-invasive arterial imaging in
predicting patient CV risk, and the need for further re-
search to override the limits of the current approach
based on traditional risk factors.
Additional interesting findings were shown in our
study. The mean cIMT in this study population was less
than the value in healthy Koreans, who were also
assessed using ultrasound high-resolution B-mode ca-
rotid artery imaging [17], with the prevalence of subclin-
ical atherosclerosis based on cIMT only (more than
average of age- and sex-specific normal values in
Koreans) found to be 15.3 % in the current study. Medi-
cations such as statins, anti-hypertensives, oral anti-
diabetic drugs, and anti-platelet agents are known to
have a variety of cardioprotective effects, including, in
some cases, positive effects on atherosclerosis [29, 30],
and patients were not excluded from this study based on
their use of such medications. For example, the biguan-
ide glucose-lowering agent, metformin, has been shown
to have a number of cardioprotective effects, including
reduction in overall CV mortality [30]; however, the dir-
ect effect of metformin on cIMT is weak [31], and met-
formin use is therefore considered unlikely to have had a
significant impact on results in the present study. Con-
versely, use of statins has been shown to decrease pro-
gression rate, or even regress, cIMT [32]. Therefore, the
findings that 60 % of our study subjects were taking sta-
tins and that the mean cIMT among statin users was
Table 3 Prevalence of subclinical atherosclerosisa by age and
sex difference
Age (years) Total (%) Men (%) Women (%)
<40 12/19 (63.2) 8/12 (66.7) 4/7 (57.1)
40–49 34/60 (56.7) 24/39 (61.5) 10/21 (47.6)
50–59 79/114 (69.3) 42/60 (70.0) 37/54 (68.5)
60–69 84/105 (80.0) 39/44 (88.6) 45/61 (73.8)
≥70 49/57 (86.0) 20/23 (87.0) 29/34 (85.3)
Total 258/355 (72.7) 133/178 (74.7) 125/177 (70.6)
aSubclinical atherosclerosis is defined as more than the average age- and
sex-matched mean cIMT or the presence of carotid plaque
cIMT, carotid intima media thickness
Fig. 1 Distribution of mean cIMT according to age and sex category
Table 4 Prevalence of subclinical atherosclerosis according to
UKPDS risk group
Men (%) Women (%)
Age
(years)
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smaller than that in non-users (although not statisti-
cally significant, Additional file 1: Table S6), may partly
explain the smaller cIMT in our study populations.
This result demonstrated that the strict control of
LDL-C could differently affect cIMT and established
plaques [31, 32]. Therefore carotid artery plaque pres-
ence seems to work as a robust measure of carotid
artery atherosclerosis in populations on various medi-
cations affecting cIMT, because although plaques may
regress after treatment with medication, complete
resolution will be rare, especially in patients with a
high risk of CVD.
Furthermore, aging was the most significant predictor
of subclinical atherosclerosis, and those who were cen-
trally obese and had diabetes for long periods, especially
among women, were more likely to have subclinical ath-
erosclerotic disease. Additional biochemical or clinical
variables were not predictive of subclinical athero-
sclerosis, which may be attributable to the relatively
homogeneous population characteristics, i.e. patients
already had two strong risk factors for atherosclerosis:
diabetes and hyperlipidemia.
We surveyed the prevalence of subclinical athero-
sclerosis in Korean patients with diabetes and hyper-
lipidemia who were at high risk for future CV events.
Carotid artery imaging with B-mode ultrasound is a
validated method for identifying subclinical athero-
sclerosis, and this technique was applied by one
skilled sonographer for all patients across all six sites,
to minimize inter- and intra-site technical variability.
A limitation of our study is that a control group,
without diabetes or hyperlipidemia, was not included
in the survey. Furthermore, patients were included
irrespective of whether they had other CV risk fac-
tors, such as overweight/obesity and hypertension.
Mean BMI values were found to be slightly higher
than the upper-normal bracket of 25 kg/m2 in both
men and women in this study (Table 1); this is per-
haps unsurprising given the known association be-
tween overweight and type 2 diabetes.
Conventional risk engines are based on clinical risk
factors and biochemical parameters that can be modified
by medications, and may underestimate CV risk in high-
risk patients. Based on the high prevalence of subclinical
atherosclerosis in diabetic patients with hyperlipidemia,
we can conclude that early screening for the detection of
subclinical atherosclerosis and more aggressive manage-
ment are warranted for patients with diabetes and hyper-
lipidemia, especially if they are elderly, have central
obesity and have a long duration of diabetes. Carotid
artery plaque presence may be a more reliable measure
of atherosclerotic burden than cIMT, as medications
such as statins may differentially affect the plaque and
the thickness of the carotid arterial wall.
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